{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fleischer LC"],"funding":["Curing Kids Cancer","NICHD NIH HHS","Hyundai Hope On Wheels","Children's Healthcare of Atlanta","National Cancer Institute","NCI NIH HHS","NIGMS NIH HHS","National Institute of Child Health and Human Development"],"pagination":["141"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6936092"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for the treatment of T cell malignancies. There are many challenges in translating this therapy for T cell disease, including fratricide, T cell aplasia, and product contamination. To the best of our knowledge, no tumor-specific antigen has been identified with universal expression on cancerous T cells, hindering CAR T cell therapy for these malignancies. Numerous approaches have been assessed to address each of these challenges, such as (i) disrupting target antigen expression on CAR-modified T cells, (ii) targeting antigens with limited expression on T cells, and (iii) using third party donor cells that are either non-alloreactive or have been genome edited at the T cell receptor α constant (TRAC) locus. In this review, we discuss CAR approaches that have been explored both in preclinical and clinical studies targeting T cell antigens, as well as examine other potential strategies that can be used to successfully translate this therapy for T cell disease."],"journal":["Journal of hematology & oncology"],"pubmed_title":["Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions."],"pmcid":["PMC6936092"],"funding_grant_id":["K12HD072245","F31CA221002","K12 HD072245","Young Investigator Grant","T32 GM008602"],"pubmed_authors":["Raikar SS","Spencer HT","Fleischer LC"],"additional_accession":[]},"is_claimable":false,"name":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.","description":"Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for the treatment of T cell malignancies. There are many challenges in translating this therapy for T cell disease, including fratricide, T cell aplasia, and product contamination. To the best of our knowledge, no tumor-specific antigen has been identified with universal expression on cancerous T cells, hindering CAR T cell therapy for these malignancies. Numerous approaches have been assessed to address each of these challenges, such as (i) disrupting target antigen expression on CAR-modified T cells, (ii) targeting antigens with limited expression on T cells, and (iii) using third party donor cells that are either non-alloreactive or have been genome edited at the T cell receptor α constant (TRAC) locus. In this review, we discuss CAR approaches that have been explored both in preclinical and clinical studies targeting T cell antigens, as well as examine other potential strategies that can be used to successfully translate this therapy for T cell disease.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Dec","modification":"2025-04-04T10:43:20.192Z","creation":"2020-05-22T01:35:17Z"},"accession":"S-EPMC6936092","cross_references":{"pubmed":["31884955"],"doi":["10.1186/s13045-019-0801-y"]}}